Reading this on a mobile device? Try our optimized mobile version here:

March 7, 2013
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
  • Drug industry heavyweights: Research cuts threaten U.S.
    Public funding of agencies that support scientific and biomedical research pays significant dividends and should be restored immediately, write former Genentech CSO Marc Tessier-Lavigne, Regeneron Pharmaceuticals Chairman P. Roy Vagelos and former NIH Director and Sanofi R&D President Elias Zerhouni. Great strides have been made in cardiovascular and HIV/AIDS research thanks to NIH funding, but Alzheimer's disease, diabetes and other chronic diseases threaten to break the nation's bank in the absence of investments in research, they write. Even before sequestration, steadily eroding funds squeezed research and sent many U.S. scientists abroad, harming U.S. competitiveness, they write. Forbes (3/6) LinkedInFacebookTwitterEmail this Story
Boehringer Ingelheim BioXcellence™ makes outsourcing easy
As a leading biopharmaceutical contract manufacturer Boehringer Ingelheim BioXcellence™ offers tailor-made contract development and manufacturing services to the biopharmaceutical industry, providing the entire production technology chain from DNA to fill and finish under one roof at its facilities in Biberach (Germany), Vienna (Austria) and Fremont (USA). Explore BI BioXcellence™
  Health Care & Policy 
  • Regulators extend Pfizer's patent on Celebrex
    The U.S. Patent & Trademark Office extended the patent on Pfizer's Celebrex until Dec. 2, 2015, for arthritis and other conditions, extending market exclusivity by a year and a half. Pfizer filed suit against Teva Pharmaceutical Industries, Mylan, Actavis (formerly Watson), Lupin and Apotex to block U.S. sales of generic versions beginning in May 2014. Reuters (3/5) LinkedInFacebookTwitterEmail this Story
  • Nanoparticles could aid fast test for infectious diseases
    A screening method that uses DNA powder and gold nanoparticles has passed tests involving the identification of malaria and sexually transmitted diseases, researchers at the University of Toronto's Institute of Biomaterials and Biomedical Engineering reported in the journal Angewandte Chemie. The test is being developed as a fast point-of-care assay for the diagnosis of multiple infections from a single small sample. (3/5) LinkedInFacebookTwitterEmail this Story
Reach Biopharmaceutical Decision-Makers with SmartBrief
You read SmartBrief, but did you know that SmartBrief publishes more than 30 unique e-newsletters for life science and health care professionals? SmartBrief delivers an engaged audience of more than a half-million business leaders, driving best-in-class click through rates and consistent reader engagement. Find out if we're reaching your target audience or contact us.
  Company & Financial News 
  Industry Deals 
  Food & Agriculture 
  Industrial & Environmental 
  • Australian group reports progress in advanced-biofuel project
    Australia-based Agritechnology has identified a site in New South Wales for a demonstration-scale advanced biofuel plant. The planned facility is expected to turn sweet sorghum, native grasses and sugarcane into renewable fuels, the company said. "We are a long way off but ultimately we'd like to provide an opportunity for farmers to have a market for feedstocks that can be used in this production," said Derek Robinson of Agritechnology. (U.K.) (3/6) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • BIOtechNOW
    BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

Scientific progress makes moral progress a necessity; for if man's power is increased, the checks that restrain him from abusing it must be strengthened."
--Anne Louise Germaine de Staël,
Swiss author

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.® Legal Information